CET

EQS-News: Marinomed Biotech AG evaluates strategic options for Carragelose portfolio

Retrieved on: 
Mercredi, décembre 20, 2023

Korneuburg, Austria, 18 December 2023 – Marinomed Biotech AG (VSE:MARI) considers strategic options for its Carragelose business and has mandated an external advisor.

Key Points: 
  • Korneuburg, Austria, 18 December 2023 – Marinomed Biotech AG (VSE:MARI) considers strategic options for its Carragelose business and has mandated an external advisor.
  • A structured process was initiated, in which Marinomed and the advisor will start engaging with potential partners.
  • This initiative meets an attractive market environment for those assets that comply with the new EU medical device regulation (MDR).
  • Carragelose is a unique, patent-protected, broadly active virus-blocking compound and is currently used in a marketed product portfolio for the prophylaxis and treatment of viral respiratory infections.

EQS-News: IKB Deutsche Industriebank AG: Tender offer to the holders of Trust Preferred Securities of IKB Funding Trust I

Retrieved on: 
Mercredi, décembre 20, 2023

[Düsseldorf, 19 December 2023] IKB Deutsche Industriebank AG (the "Bidder") hereby gives notice of its tender offer to the holders of the securities issued by IKB Funding Trust I (ISIN DE0008592759, the "Securities") to purchase them at a purchase price equal to 69.50% of the principal amount in accordance with the terms and subject to the conditions of the Tender Offer Memorandum dated 19 December 2023.

Key Points: 
  • [Düsseldorf, 19 December 2023] IKB Deutsche Industriebank AG (the "Bidder") hereby gives notice of its tender offer to the holders of the securities issued by IKB Funding Trust I (ISIN DE0008592759, the "Securities") to purchase them at a purchase price equal to 69.50% of the principal amount in accordance with the terms and subject to the conditions of the Tender Offer Memorandum dated 19 December 2023.
  • The offer begins today, 19 December 2023, and ends on 24 January 2024 at 17:00 (CET), subject to extension.
  • In order to accept the offer, Securityholders must submit acceptances to their custodian or the direct participant through which they hold their Securities by the expiration deadline of the Offer.
  • Securityholders who require assistance in accepting the offer should contact the Dealer Manager at the address below or their custodian.

Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators

Retrieved on: 
Lundi, novembre 20, 2023

Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators

Key Points: 
  • Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators
    Paris, France, November 20, 2023 – 5:45 pm (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, whose safeguard proceedings (procédure de sauvegarde) were converted into receivership (redressement judiciaire) by decision of the Paris Commercial Court on November 13, 2023, announces that the court-appointed administrators have today received a takeover offer for the assets and activities of Pixium.
  • The date for the hearing to examine the takeover offer will be set by the Commercial Court by the end of November.
  • The Company draws investors’ attention to the fact that, given the current offer and the Company’s level of indebtedness, the sale proceeds received in the context of the Company’s insolvency proceedings do not allow a total or partial reimbursement of shareholders.

Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

Retrieved on: 
Lundi, novembre 20, 2023

The KALAHARI trial is the only ongoing trial sponsored by Oxurion.

Key Points: 
  • The KALAHARI trial is the only ongoing trial sponsored by Oxurion.
  • The KALAHARI trial evaluated Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy.
  • Said Tom Graney, CEO, “We are deeply disappointed that the topline data from the KALAHARI trial did not show improvement in vision from THR-149.
  • I would personally like to thank the incredible team at Oxurion for designing and executing a trial that yielded clearly interpretable results.

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

Retrieved on: 
Vendredi, novembre 17, 2023

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) --  Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Key Points: 
  • NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) --  Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
  • The notice of meeting as published today in the BALO (Bulletin des Annonces Legales Obligatoires), including the agenda, the text of the resolutions and the terms of participation, is online on the Cellectis website at the following address:

ONWARD® Reports Q3 Business Update and Year-To-Date Highlights

Retrieved on: 
Jeudi, novembre 16, 2023

The study participant also received a wireless brain-computer interface (BCI), designed to initiate thought-driven movement when paired with ARC-IM.

Key Points: 
  • The study participant also received a wireless brain-computer interface (BCI), designed to initiate thought-driven movement when paired with ARC-IM.
  • ONWARD ARC-IM delivers targeted, programmed ARC-IM Therapy to the spinal cord to restore movement and other functions after SCI.
  • To date, ARC-IM Therapy has been applied across multiple clinical feasibility studies to restore mobility or stabilize blood pressure after SCI.
  • In September, the Company announced a partnership with Lovell Government Services (Lovell), a Service-Disabled Veteran-Owned Small Business (SDVOSB).

Navitas Highlights Leading-Edge, Next-gen Industrial Power at Munich Power Semiconductor User Forum 2023

Retrieved on: 
Jeudi, novembre 16, 2023

TORRANCE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS) , the industry leader in next-generation GaNFast™ gallium nitride (GaN) and GeneSiC™ silicon carbide (SiC) power semiconductors, today announced its participation in the Power Semiconductor User Forum , organized by WEKA Fachmedien on November 22nd -23rd, 2023.

Key Points: 
  • TORRANCE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS) , the industry leader in next-generation GaNFast™ gallium nitride (GaN) and GeneSiC™ silicon carbide (SiC) power semiconductors, today announced its participation in the Power Semiconductor User Forum , organized by WEKA Fachmedien on November 22nd -23rd, 2023.
  • Alfred Hesener, Senior Director of Industrial and Consumer Applications will explore “Reliability and Cost-of-Ownership Optimization in Industrial Power Supplies,” on November 23rd at 1:45 p.m. CET.
  • Navitas’ GaNFast power ICs integrate GaN power and drive with control, sensing, and protection to enable faster charging, higher power density, greater energy savings and system cost reduction.
  • “For industrial power designers, the WEKA forum highlights leading-edge, reliable technology for drives, pumps, chargers and power conversion, using GaN and SiC,” said Mr. Hesener.

Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program   Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year

Retrieved on: 
Jeudi, novembre 16, 2023

This is the third installment of the EUR 3.5 million in unconditional funding agreed with Atlas allowing the Company to reach the topline data of the Phase 2, Part B of the KALAHARI trial, expected by the end of this year.

Key Points: 
  • This is the third installment of the EUR 3.5 million in unconditional funding agreed with Atlas allowing the Company to reach the topline data of the Phase 2, Part B of the KALAHARI trial, expected by the end of this year.
  • Under the Funding Program, Atlas has committed to up to EUR 20 million in funding over a 24-month period, of which it has now subscribed to EUR 11.5 million, leaving a remainder of EUR 8.5 million.
  • Tom Graney, CEO of Oxurion, said: “We are very focused right now on reaching the key catalyst of reporting the topline data from the KALAHARI trial this year.
  • With the sustained support from Atlas, we expect to achieve that milestone without the need for additional capital.

Aegon’s trading update for third quarter 2023

Retrieved on: 
Jeudi, novembre 16, 2023

We expect the full-year 2023 operating capital generation from the units to be around EUR 1.2 billion; up from the previous guidance of more than EUR 1.0 billion.

Key Points: 
  • We expect the full-year 2023 operating capital generation from the units to be around EUR 1.2 billion; up from the previous guidance of more than EUR 1.0 billion.
  • As outlined at our Capital Markets Day 2023 in June, a key strategic focus is to ensure that our US business, Transamerica, reaches its full potential.
  • In the third quarter, Transamerica’s Strategic Assets have continued to deliver growth.
  • Second half 2023 results – March 1, 2024
    First quarter 2024 trading update – May 16, 2024
    Annual General Meeting – June 12, 2024
    First half 2024 results – August 22, 2024
    The conference call and Q&A can be followed via a live audio webcast on our website.

IDEX Biometrics ASA - Contemplated Private Placement

Retrieved on: 
Mercredi, novembre 15, 2023

IDEX Biometrics ASA (the "Company"), a leading provider of advanced fingerprint identification and authentications solutions, has retained Arctic Securities AS as sole manager and bookrunner (the "Manager") to advise on and effect a private placement (the "Private Placement") of new shares in the Company (the "Offer Shares") to raise gross proceeds of up to NOK 35 million.

Key Points: 
  • IDEX Biometrics ASA (the "Company"), a leading provider of advanced fingerprint identification and authentications solutions, has retained Arctic Securities AS as sole manager and bookrunner (the "Manager") to advise on and effect a private placement (the "Private Placement") of new shares in the Company (the "Offer Shares") to raise gross proceeds of up to NOK 35 million.
  • With such cost reductions and the combined proceeds from the contemplated Private Placement and Convertible Bond, the Company expects to be fully funded through 2024.
  • The subscription price per Offer Share in the Private Placement (the "Offer Price") and the number of Offer Shares to be issued in the Private Placement will be determined by the board of directors of the Company (the "Board") following an accelerated bookbuilding process.
  • A private placement enables the Company to raise capital in an efficient manner, and the Private Placement is structured to ensure that a market-based subscription price is achieved.